PubMed · 16437752
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
Carmen Ginghinã. 2006-01-24. A view from Bucharest.. https://pubmed.ncbi.nlm.nih.gov/16437752/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
BACKGROUND: Malaysia like many other countries worldwide uses spontaneous reporting systems as a mean of collecting data on suspected adverse drug reaction (ADR). However, compared to other countries, which use the system, the reporting rate in Malaysia is very low. Why some physicians do not report ADRs is not well understood. OBJECTIVE: To identify factors, which would predict physicians' failure to send ADR reports. DESIGN AND SETTING: Face-to-face interview using a structured questionnaire involving physicians working at the University of Malaya Medical Centre, Malaysia. RESULTS: About a third of the physicians in the Centre participated. Sixty-five of the 415 approached refused to participate. A high proportion of the respondents (81.4%) indicated that they had suspected an ADR but did not report it, while about 40% of the respondents were not aware of the existence of the national reporting system in Malaysia. Logistic regression modelling identified the variable 'ADR considered to be too trivial or too well known to report' as the strongest predictor of not reporting, followed by physicians' category and uncertainty that the reaction had been definitely caused by a drug. CONCLUSION: Important predictor variables, which limit physicians from reporting ADR in Malaysia, were related to uncertainty of types of reaction to report, lack of awareness about the existence, function and purpose of national ADR reporting. The findings could be useful for planning strategies to improve the reporting rate.
BACKGROUND: The introduction of Diagnosis-Related Groups, which standardize payment for each clinical service, entails keeping the inpatient treatment as short as possible. Thus outpatient treatment is gaining in importance. To cope with this change, organizational and structural modifications of clinic routine are necessary. METHODS: In the ear, nose, and throat outpatient clinic of Johann Wolfgang Goethe University in Frankfurt, Germany, a hotline was established that allows patients to make appointments and get advice based on quality management guidelines according to DIN EN ISO 9001:2000. The development of this project is described here step by step, from planning to inclusion in the daily clinic routine. RESULTS: Patient visits became more effective despite increasing demand. This resulted in high satisfaction of patients and clinic personnel alike. CONCLUSION: This model may contribute considerably to coping with the increasing demand for clinic appointments and to optimal use of a clinic's human resources.
PURPOSE: The importance of understanding the revenue cycle, reviewing the billing system for errors, and collaborating with other health system departments in maximizing pharmaceutical reimbursement, and the approach used at a large academic medical center to justify a reimbursement specialist and achieve this goal are discussed. SUMMARY: Understanding the revenue cycle may enable pharmacy departments to make wise decisions about programs and services that maximize revenue recovery and meet patient needs. Parts of the revenue cycle that pharmacists can have a favorable effect on include claim denials/payment variances, regulatory changes, compliance, contracting, and price setting. Pharmaceutical reimbursement was increased substantially at one institution through a collaborative effort involving multiple departments and a reimbursement specialist who analyzed the revenue cycle, reviewed billing systems, and took steps to avoid or correct billing errors. CONCLUSION: Collaborating with members of key health system departments can help identify and resolve billing system errors that diminish revenue. Documenting efforts to increase revenue recovery can help justify adding personnel dedicated to reimbursement matters. Analyzing the revenue cycle can contribute to wise decision-making that optimizes pharmaceutical reimbursement.